MedTrace Logo

Prospective Study for the Application of Cytosorb® in Critically Ill Patients

NCT04913298 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-02-22

No results posted yet for this study

Summary

The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation, rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis, polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly retrospectively, there are no data on real-time elimination performance and saturation kinetics during the course of treatment. These questions should be answered by the present study.

Conditions

  • Rhabdomyolysis
  • Acute Liver Injury
  • Cytokine Storm

Interventions

DEVICE

Cytosorb therapy

Start of Cytosorb therapy is at the discretion of the attending physician

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-04-30
Completion
2023-12-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913298 on ClinicalTrials.gov